REGENXBIO Stock Earnings Estimates Raised by HC Wainwright

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at HC Wainwright boosted their FY2026 earnings per share estimates for shares of REGENXBIO in a research note issued to investors on Friday, November 6th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($3.15) for the year, up from their prior estimate of ($3.65). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($3.26) per share. HC Wainwright also issued estimates for REGENXBIO’s Q4 2026 earnings at ($1.19) EPS, Q1 2027 earnings at ($1.19) EPS, Q2 2027 earnings at ($1.13) EPS, Q3 2027 earnings at ($1.07) EPS, Q4 2027 earnings at ($1.03) EPS and FY2027 earnings at ($4.41) EPS.

A number of other equities analysts have also weighed in on RGNX. Robert W. Baird cut their price objective on shares of REGENXBIO from $32.00 to $29.00 and set an “outperform” rating for the company in a research report on Tuesday, August 25th. UBS Group restated a “positive” rating on shares of REGENXBIO in a research report on Friday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a research note on Friday, September 4th. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Mizuho set a $18.00 price target on REGENXBIO in a report on Friday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, REGENXBIO presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.18.

REGENXBIO Price Performance

Shares of NASDAQ RGNX opened at $8.07 on Tuesday. The company has a market cap of $532.70 million, a PE ratio of -2.51 and a beta of 1.24. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19. The company has a 50-day simple moving average of $7.77 and a 200-day simple moving average of $9.02.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, November 5th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.67. The company had revenue of $9.16 million for the quarter, compared to analyst estimates of $10.89 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%.

Institutional Investors Weigh In On REGENXBIO

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in REGENXBIO during the second quarter worth approximately $76,641,000. Dimensional Fund Advisors LP boosted its holdings in shares of REGENXBIO by 11.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,010,381 shares of the biotechnology company’s stock valued at $8,464,000 after purchasing an additional 106,530 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of REGENXBIO in the 2nd quarter valued at $6,212,000. Corient Private Wealth LP purchased a new stake in shares of REGENXBIO during the 2nd quarter valued at $2,608,000. Finally, Deutsche Bank AG purchased a new stake in shares of REGENXBIO during the 2nd quarter valued at $2,490,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. The company’s programs use adeno-associated virus (AAV) vectors to deliver genetic material to targeted cells, with the goal of addressing the underlying causes of disease rather than primarily treating symptoms.

REGENXBIO’s technology is built around its NAV AAV Technology Platform, which supports the design and development of gene-delivery vectors. Its pipeline has included investigational therapies for conditions such as Duchenne muscular dystrophy, Hunter syndrome, age-related macular degeneration and other rare diseases.